| pubmed-article:1403033 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1403033 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:1403033 | lifeskim:mentions | umls-concept:C0023516 | lld:lifeskim |
| pubmed-article:1403033 | lifeskim:mentions | umls-concept:C0002199 | lld:lifeskim |
| pubmed-article:1403033 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:1403033 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:1403033 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:1403033 | lifeskim:mentions | umls-concept:C0441767 | lld:lifeskim |
| pubmed-article:1403033 | lifeskim:mentions | umls-concept:C0677850 | lld:lifeskim |
| pubmed-article:1403033 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:1403033 | pubmed:dateCreated | 1992-10-30 | lld:pubmed |
| pubmed-article:1403033 | pubmed:abstractText | A prospective study in breast cancer patients was undertaken to determine whether escalating doses of doxorubicin and cyclophosphamide would result in a higher fraction of patients free of disease, and to evaluate the role of leukocyte alpha-interferon. | lld:pubmed |
| pubmed-article:1403033 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1403033 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1403033 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1403033 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1403033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1403033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1403033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1403033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1403033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1403033 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1403033 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1403033 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:1403033 | pubmed:author | pubmed-author:SmithT LTL | lld:pubmed |
| pubmed-article:1403033 | pubmed:author | pubmed-author:GuttermanJ... | lld:pubmed |
| pubmed-article:1403033 | pubmed:author | pubmed-author:LawR ERE | lld:pubmed |
| pubmed-article:1403033 | pubmed:author | pubmed-author:HortobagyiG... | lld:pubmed |
| pubmed-article:1403033 | pubmed:author | pubmed-author:BuzdarA UAU | lld:pubmed |
| pubmed-article:1403033 | pubmed:author | pubmed-author:AmesF CFC | lld:pubmed |
| pubmed-article:1403033 | pubmed:author | pubmed-author:HolmesF AFA | lld:pubmed |
| pubmed-article:1403033 | pubmed:author | pubmed-author:FraschiniGG | lld:pubmed |
| pubmed-article:1403033 | pubmed:author | pubmed-author:SingletaryS... | lld:pubmed |
| pubmed-article:1403033 | pubmed:author | pubmed-author:HugV MVM | lld:pubmed |
| pubmed-article:1403033 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1403033 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:1403033 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1403033 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1403033 | pubmed:pagination | 1540-6 | lld:pubmed |
| pubmed-article:1403033 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:meshHeading | pubmed-meshheading:1403033-... | lld:pubmed |
| pubmed-article:1403033 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1403033 | pubmed:articleTitle | Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. | lld:pubmed |
| pubmed-article:1403033 | pubmed:affiliation | Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77030. | lld:pubmed |
| pubmed-article:1403033 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1403033 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1403033 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:1403033 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:1403033 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1403033 | lld:pubmed |
